The search strategies included the Medical Subject Heading (MeSH) term 'economics', and the MeSH entry terms 'cost', 'cost effectiveness', 'value', and 'cost utility', as well as all names for GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors. Inclusion criteria included (1...
Patients initiating SGLT2 inhibitors also experienced a decreased risk of Article Information Authors’ Full Names and Academic Degrees Min Zhuo, MD, MPH, Julie M. Paik, MD, ScD, MPH, Deborah J. Wexler, MD, MSc, Joseph V. Bonventre, MD, PhD, Seoyoung C. Kim, MD, ScD, and Elisabetta...
SGLT2 inhibitors have been associated with an increased risk of euglycemic diabetic ketoacidosis (DKA).71,72 An observational study of patients in the United States identified several risk factors for hospitalization owing to SGLT2 inhibitor-associated DKA, including use of digoxin or medication for ...
Medication Adherence to SGLT2 Inhibitors vs. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: A Meta-Analysisdoi:10.1681/ASN.20245w2bgaw1Whitney SussmanErin R. WeedaConner Elizabeth JohnsonAmerican Society of NephrologyJournal of the American Society of Nephrology...
We compared SGLT2i use in Alberta and Manitoba, to Ontario. We examined metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitor as control cases. Poisson regression was used to estimate confounder-adjusted prevalence ratios for the use of each medication. Results We included 3,191 adults (...
While incretin modulation has been a popular therapeutic intervention (beyond RAAS modulation) to combat DN, SGLT2 inhibitors have gained acceptance in dual (with metformin) and triple therapy modes (metformin and sulfonylurea) in prevalent anti-type2 diabetic medication (Clar et al., 2012). GLP-...
Including SGLT2-Inhibitors in the PQA diabetes medication dosing (DOS) measure may improve identification of high-risk patientsdoi:10.1016/j.sapharm.2018.03.051Xie SujiMukherjee DhritimanNaples JenniferThelus RosenieDefreitas ErikKress AdrianResearch in Social & Administrative Pharmacy...
More recently, SGLT2 inhibitors were implemented in the heart failure guidelines of the European Society of Cardiology (ESC) for patients with HFrEF [2]. This recommendation is independent of the presence of diabetes mellitus despite the history of this drug class as an anti-diabetic medication. ...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and metformin are both widely accepted anti-hyperglycemic agents. However, there is still no systematic review evaluating the cardiovascular benefits and risk of infections of SGLT2i versus metformin. To make that clear, we designed this study. Publ...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and metformin are both widely accepted anti-hyperglycemic agents. However, there is still no systematic review evaluating the cardiovascular benefits and risk of infections of SGLT2i versus metformin. To make that clear, we designed this study. Publ...